Prospective Immunophenotyping of CD8<sup>+</sup> T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30205124.
- Also identified by DOI 10.1016/j.ijrobp.2018.09.001 and PMC identifier 6301146.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examined the effects of metastasis-directed stereotactic body radiation therapy (mdSBRT) on CD8<sup>+</sup> T-cell subpopulations and correlated post-mdSBRT immunophenotypic responses with clinical outcomes in patients with oligometastatic prostate cancer (OPCa). Peripheral blood mononuclear cells were prospectively isolated from 37 patients with OPCa (≤3 metastases) who were treated with mdSBRT. Immunophenotyping identified circulating CD8<sup>+</sup> T-cell subpopulations, including tumor-reactive (T<sub>TR</sub>), effector memory, central memory (T<sub>CM</sub>), effector, and naïve T cells from samples collected before and after mdSBRT. Univariate Cox proportional hazards regression was used to assess whether changes in these T-cell subpopulations were potential risk factors for death and/or progression. The Kaplan-Meier method was used for survival. Cumulative incidence for progression and new distant metastasis weas estimated, considering death as a competing risk. Median follow-up was 39 months (interquartile range, 34-43). Overall survival at 3 years was 78.2%. Cumulative incidence for local progression and new distant metastasis at 3 years was 16.5% and 67.6%, respectively. Between baseline and day 14 after mdSBRT, an increase in the T<sub>CM</sub> cell subpopulation was associated with the risk of death (hazard ratio, 1.22 [95% confidence interval, 1.02-1.47]; P = .033), and an increase in the T<sub>TR</sub> cell subpopulation was protective against the risk of local progression (hazard ratio, 0.80 [95% confidence interval, 0.65-0.98]; P = .032). An increase in the T<sub>TR</sub> cell subpopulation was protective against the risk of disease progression, and an increase in the T<sub>CM</sub> cell subpopulation was associated with the risk of death in patients with OPCa treated with mdSBRT. Disease control may be further improved by better understanding the CD8<sup>+</sup> T-cell subpopulations and by enhancing their antitumor effect.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Prostatic Neoplasms
- Radiosurgery